The latest sign of momentum in Congress to pass legislation reforming FDA's process for making changes to the OTC drug monograph also creates a potential impediment to swift passage. A House bill introduced March 19 would allow 18-month market exclusivity periods for some innovative consumer products introduced under the proposed new monograph system, but the Senate bill introduced earlier calls for two-year periods.
The length of exclusivity periods is the only major difference in the bills, both largely based on a proposal developed by FDA and drug industry representatives, and committees in both...
The Consumer Healthcare Products Association, a prominent participant in working with FDA officials on developing the framework for monograph reform, expects the industry will accept the House bill's 18-month exclusivity.